Sensei Biotherapeutics to Present at Upcoming Conferences

Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage immuno-oncology company focused on developing next-generation therapeutics for cancer patients [2] Group 1: Upcoming Conferences - Company management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET [1] - The company will also participate in the 2024 Cantor Fitzgerald Global Healthcare Conference on September 18, 2024, at 2:30 p.m. ET [1] - Webcasts of both presentations will be available on the Investors section of the Sensei website for approximately 90 days following the events [1] Group 2: Product Development - Sensei Biotherapeutics utilizes its TMAb™ platform to develop conditionally active therapeutics that target the tumor microenvironment [2] - The lead investigational candidate, SNS-101, is designed to block the VISTA checkpoint selectively within the low pH tumor microenvironment [2] - Other candidates in development include SNS-102 targeting VSIG-4, SNS-103 targeting ENTPDase1 (CD39), and SNS201, a bispecific antibody combining CD28 agonist and anti-VISTA components [2]